An everolimus test determines the level of this medication in the blood. Everolimus is used to treat certain types of cancer or to prevent rejection of transplanted organs by suppressing the immune system. This test helps the physician monitor treatment efficacy and avoid potential adverse effects by maintaining an optimal concentration of the drug in the blood.
Everolimus is a medication similar to sirolimus that is used to suppress the immune system after organ transplantation to prevent rejection, as well as as adjunctive therapy for certain types of kidney cancer and other malignant tumors. Like sirolimus, everolimus acts by inhibiting mTOR, a key enzyme that regulates cell growth and proliferation.
By blocking the mTOR signaling pathway, everolimus suppresses the growth of cancer cells and the proliferation of T lymphocytes, which underlies its antitumor and immunosuppressive effects in organ transplantation. Everolimus is extensively metabolized, primarily by cytochrome P450 (CYP) 3A4; therefore, concomitant use with inducers or inhibitors of this enzyme may require dose adjustment. The most common adverse effects include hyperlipidemia, thrombocytopenia, and nephrotoxicity. Monitoring everolimus levels helps the physician maintain an optimal concentration of the drug to ensure effective treatment and prevent adverse effects.
Everolimus level testing is indicated for patients taking this medication as prescribed by a physician after heart or kidney transplantation, to monitor immunosuppression and prevent rejection of the transplanted organ. The physician may order this test to maintain the target blood concentration of the drug (generally 3–8 ng/mL immediately before the next dose), which provides the best treatment outcomes while minimizing the risk of complications. Therapeutic targets vary depending on the type of transplant and the institution's protocol. Although monitoring everolimus levels during cancer treatment is generally accepted, a physician may order this test in individual cases.
It is important to have blood drawn for everolimus testing while fasting, after a certain period following the last dose (usually immediately before the next scheduled dose; however, this should be confirmed with the physician). Inform the physician about all other medications you are taking, as they may affect everolimus concentrations.
